The three main types of blood cancer are leukemia, lymphoma, and multiple myeloma. Each one starts in a different type of blood cell and behaves differently in the body, but all three disrupt the normal production or function of blood cells. Together, they account for roughly 10% of all new cancer diagnoses in the United States each year.
Leukemia: Cancer of White Blood Cells
Leukemia develops when white blood cells in the bone marrow grow out of control. These abnormal cells crowd out healthy blood cells, making it harder for the body to fight infections, carry oxygen, and control bleeding. Some forms progress rapidly (acute leukemia), while others grow slowly over months or years (chronic leukemia).
There are four primary subtypes, organized by how fast they grow and which cell line they affect:
- Acute lymphocytic leukemia (ALL) is the most common childhood cancer, though it also occurs in adults. It affects cells called lymphocytes.
- Acute myeloid leukemia (AML) is more common in older adults. It affects immature cells that would normally develop into white blood cells, red blood cells, or platelets.
- Chronic lymphocytic leukemia (CLL) is one of the most common leukemias in adults and typically appears during or after middle age. It tends to progress slowly, and some people don’t need treatment for years.
- Chronic myeloid leukemia (CML) also usually occurs in middle-aged or older adults and grows gradually.
An estimated 67,790 new cases of leukemia will be diagnosed in the U.S. in 2026. Acute forms often cause sudden symptoms like fatigue, frequent infections, easy bruising, and unexplained weight loss. Chronic forms may produce no symptoms at all in early stages and are sometimes caught during routine blood work.
Lymphoma: Cancer of the Lymphatic System
Lymphoma starts in the lymphatic system, the network of lymph nodes, the spleen, and bone marrow tissue that helps your body filter waste and fight infection. It develops when lymphocytes, a type of white blood cell that normally patrols for threats, begin to multiply abnormally and collect in lymph nodes or other organs.
Lymphoma is divided into two main categories: Hodgkin lymphoma and non-Hodgkin lymphoma. The distinction comes down to a specific cell. If a pathologist finds large, abnormal cells called Reed-Sternberg cells under the microscope, the diagnosis is Hodgkin lymphoma. If those cells are absent, it’s non-Hodgkin lymphoma.
Beyond that microscopic difference, the two types behave differently. Hodgkin lymphoma almost always arises from B lymphocytes and tends to start in lymph nodes in the neck, chest, groin, or armpits, spreading in an orderly pattern from one node group to the next. Non-Hodgkin lymphoma can develop from B cells, T cells, or natural killer cells, and it’s less predictable in where it shows up. It can start in lymph nodes but is also commonly found outside of them, in organs like the stomach, skin, or brain.
Non-Hodgkin lymphoma is far more common, with dozens of subtypes that range from very slow-growing (indolent) to aggressive. Hodgkin lymphoma is less common but has high cure rates, particularly in younger patients. The most noticeable early symptom for both types is painless swelling of a lymph node, often in the neck, armpit, or groin. Some people also experience drenching night sweats, unexplained fevers, or significant weight loss.
Multiple Myeloma: Cancer of Plasma Cells
Multiple myeloma targets plasma cells, a specialized type of white blood cell that produces antibodies. Normally, when bacteria or viruses enter the body, some B cells mature into plasma cells and make antibodies tailored to fight that specific invader. In myeloma, cancerous plasma cells multiply in the bone marrow and produce a useless antibody protein called M protein that the body doesn’t need and that can’t fight infection.
This creates a cascade of problems. As myeloma cells accumulate, they crowd the bone marrow and reduce production of healthy red blood cells, white blood cells, and platelets. That leads to anemia, increased infections, and bleeding problems. The excess M protein can thicken the blood and damage the kidneys. Myeloma cells also directly weaken bone, which is why bone pain, particularly in the spine or ribs, is one of the hallmark symptoms. Fractures from minimal trauma are common.
The five-year relative survival rate for myeloma is about 64%, based on recent data from the National Cancer Institute. When the disease is caught at an early, localized stage, that number rises above 80%. Myeloma is more common in people over 65 and is roughly twice as common in Black Americans as in white Americans.
How Blood Cancers Are Diagnosed
A complete blood count (CBC) is usually the first test that raises suspicion. It measures the numbers of red blood cells, white blood cells, and platelets in your blood. Abnormally high or low counts, or the presence of immature cells, can signal a problem. A CBC alone can’t confirm a diagnosis, but it’s the reason many blood cancers are initially flagged.
From there, diagnosis typically involves a bone marrow biopsy, where a needle is used to withdraw a small sample of marrow, usually from the hip bone. A technique called immunophenotyping examines the surface markers on cells in that sample to identify exactly which type of blood cell has become cancerous and how mature it is. This step is essential for distinguishing between subtypes of leukemia, lymphoma, and myeloma, since treatment varies significantly depending on the specific diagnosis.
For lymphoma, a biopsy of a swollen lymph node is often the key step. For myeloma, blood and urine tests look for abnormal proteins like M protein. Imaging scans help identify bone damage or tumors outside the bone marrow.
Treatment Approaches
Treatment for blood cancers has shifted substantially in recent years. Targeted therapies and immunotherapies are increasingly replacing or supplementing traditional chemotherapy. These newer treatments work by attacking specific proteins or enzymes that cancer cells rely on to survive and grow, which often means fewer side effects than chemotherapy’s broad-spectrum approach.
For acute leukemias like AML, a stem cell transplant can be curative, though not everyone is a candidate. Patients typically need initial treatment to reduce cancer in the bone marrow before transplant becomes an option. For chronic leukemias like CLL and CML, targeted pills that block specific enzymes involved in cancer cell growth have become standard first-line treatment, and many patients take them long-term with good disease control.
Lymphoma treatment depends heavily on the subtype. Some indolent non-Hodgkin lymphomas are monitored without treatment until they progress. Aggressive lymphomas are treated with combination regimens, and newer immunotherapy drugs called bispecific antibodies are showing strong results for patients whose lymphoma returns after initial treatment. Hodgkin lymphoma remains one of the most curable cancers, with most patients achieving long-term remission.
Multiple myeloma is generally not considered curable, but treatment can control the disease for many years. Combinations of targeted therapy, immunotherapy, and sometimes stem cell transplant are used to push the disease into remission. Many patients go through cycles of treatment and remission over the course of years or even decades, with survival times steadily improving as newer therapies become available.